Key points
- 31,161,833 new ordinary shares were approved for quotation on the ASX on 5 Nov 2025, stemming from the exercise/vesting of performance options, not a cash placement. No consideration was paid for the shares.
- The company filed a Cleansing Notice under s708A(5)(e) confirming the shares were issued without disclosure under Part 6D.2 of the Corporations Act, that DroneShield has complied with Chapter 2M and sections 674/674A, and that there is no excluded information.
- Share price reaction: after sliding ~7.5% on Wednesday (ASX), coverage today shows European trading (Tradegate) down ~8.3% around midday.
- The vesting relates to DroneShield’s achievement of a $200m 12‑month cash‑receipts milestone and was detailed in a “Performance Options Update” on 4 Nov. Company Announcements
- Context: The company also disclosed a A$25.3m Latin American defence order earlier this week; despite the pullback, shares remain far above January levels, with one local market brief noting they were up ~406% YTD as of Wednesday afternoon.
What happened today (Nov 6)
DroneShield shares continued to feel the aftershocks of mid‑week filings. European quotations on Tradegate showed the stock lower by about 8.3% to €2.04 at 11:30 CET on Thursday, extending Wednesday’s weakness on the ASX.
The slide follows confirmation that 31,161,833 new DroneShield shares were approved for quotation on 5 November. The ASX Appendix 2A filing makes clear these shares arose from options/performance rights being exercised/converted, with nil cash consideration. In other words, this was dilution from award vesting, not a fresh capital raising.
A companion Cleansing Notice—the standard disclosure that enables trading of shares issued without a prospectus—confirms the legal basis (Part 6D.2) and that the company is compliant with financial reporting and continuous disclosure obligations, with no “excluded information” withheld from the market. Company Announcements
How big is the dilution?
The 31.16m shares represent ~3.56% of the pre‑issue register (or ~3.44% of the post‑issue count). After the quotation, total ordinary shares on issue are listed as 905,971,540. The filing also notes remaining unquoted options on issue, while the Performance Options Update indicates that 44,455,000 options vested on 4 Nov after DroneShield hit $200m in rolling 12‑month cash receipts. If all newly vested options were exercised, shares on issue would rise to ~919.3m.
Notably, the Appendix 2A shows that a portion of the newly quoted shares came from key management personnel exercising options (including CEO Oleg Vornik and directors), which can add to near‑term supply if holders decide to sell.
Why the market is jittery
Investors often react negatively when large blocks of new shares enter the market—even when tied to performance milestones—because they increase free float and dilute per‑share metrics. That caution was visible yesterday on the ASX, where the stock fell about 7.5%, and is echoed in today’s European trading.
Some German‑language coverage has framed the development as a “capital measure” that “put the stock under pressure.” The primary filings, however, indicate no cash was raised; the new shares result from employee/management option vesting linked to performance hurdles. (The site‑filed language explicitly records “nil consideration”.) FinanzNachrichten.de+1
The bigger picture: contracts and momentum
The dilution headwind landed just after DroneShield announced a A$25.3 million defence order in Latin America (deliveries across late‑2025/early‑2026), underscoring still‑strong demand for counter‑UAS and electronic‑warfare systems. Even with this week’s pullback, commentary this week noted the stock remains several‑fold above its level at the start of the year.
What to watch next
- Selling pressure: Monitor whether newly issued shares increase near‑term supply from employees/executives and how volumes evolve. The Change of Director’s Interest Notices lodged late Wednesday detail some conversions to ordinary shares.
- Option overhang: The 4 Nov update reset the next performance hurdles to $300m/$400m/$500m of revenues or rolling cash receipts, while capping future new options to ≤1% of issued capital—important for assessing future dilution cadence.
- Execution pipeline: The Latin America award adds to a busy backlog; investors will look for conversion of pipeline and cash receipts as 2026 approaches.
- Price discovery: As of publication, some trackers show the ASX price near A$3.40 after Thursday’s drop; intraday swings have been wide. Treat third‑party quotes as indicative and refer to your broker/ASX feed for live data.
Quick FAQ
Is this a capital raise?
No. The Appendix 2A states the shares were issued from the exercise/vesting of options/performance rights and for nil consideration. A Cleansing Notice was issued to allow trading without a prospectus.
How many shares are on issue now?
905,971,540 ordinary shares after the new shares were quoted (post‑issue figure reported in the filing).
How much dilution does 31.16m shares represent?
Roughly ~3.56% vs. pre‑issue shares (or ~3.44% of the post‑issue register). That excludes any future exercises of remaining options.
Why did the stock fall anyway?
Fresh supply from newly quoted shares and a large vesting announcement can pressure prices, even amid strong fundamentals and new orders. Coverage on 6 Nov shows further weakness in European trading after ~7.5% ASX losses on 5 Nov.
Sources (Nov 6, 2025)
- ASX Appendix 2A: 31,161,833 shares to be quoted; nil consideration; KMP exercises; issued capital after quotation.
- Cleansing Notice (s708A(5)(e)): issued without disclosure; compliance; no excluded information.
- Performance Options Update (4 Nov): 44,455,000 options vested on $200m 12‑month cash‑receipts milestone; future hurdles.
- ASX daily list (5 Nov): sequence of filings (Appendix 2A, Cleansing Notice, director notices).
- Price/coverage: ASX Wednesday decline (~7.5%); today’s midday European move (Tradegate).
- Contract context: A$25.3m Latin American order.
This article is for information only and is not investment advice. Always conduct your own research or consult a licensed adviser before making investment decisions.
